Prognostic factors of local control and disease free survival in centrally located non-small cell lung cancer treated with stereotactic body radiation therapy-Reference-Cited by-同舟云学术

Prognostic factors of local control and disease free survival in centrally located non-small cell lung cancer treated with stereotactic body radiation therapy

Published:2020-04-14 Issue:7 Volume:59 Page:809-817
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Duijm Marloes¹,van der Voort van Zyp Noëlle C.²,Granton Patrick V.¹,van de Vaart Paul²,Mast Mirjam E.²,Oomen-de Hoop Esther¹,Hoogeman Mischa S.¹,Nuyttens Joost J.¹

Affiliation:

1. Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands;

2. Department of Radiation Oncology, Haaglanden MC, The Hague, The Netherlands

Publisher

Informa UK Limited

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2020.1750693

Reference35 articles.

1. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline

2. ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer

3. Excessive Toxicity When Treating Central Tumors in a Phase II Study of Stereotactic Body Radiation Therapy for Medically Inoperable Early-Stage Lung Cancer

4. Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus

5. Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial;Radiotherapy and Oncology;2023-05

2. CT radiomics-based long-term survival prediction for locally advanced non-small cell lung cancer patients treated with concurrent chemoradiotherapy using features from tumor and tumor organismal environment;Radiation Oncology;2022-11-16

3. The Clinical Outcomes, Prognostic Factors and Nomogram Models for Primary Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy;Frontiers in Oncology;2022-03-01